Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Sanara MedTech (SMTI) over the last 6 years, with Q3 2025 value amounting to $123591.0.

  • Sanara MedTech's Gains from Sales and Divestitures rose 4642.27% to $123591.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $123591.0, marking a year-over-year increase of 4642.27%. This contributed to the annual value of $105875.0 for FY2024, which is 2312.3% down from last year.
  • Sanara MedTech's Gains from Sales and Divestitures amounted to $123591.0 in Q3 2025, which was up 4642.27% from $113252.0 recorded in Q2 2025.
  • In the past 5 years, Sanara MedTech's Gains from Sales and Divestitures registered a high of $154307.0 during Q4 2022, and its lowest value of $51656.0 during Q1 2024.
  • Its 5-year average for Gains from Sales and Divestitures is $102973.1, with a median of $113252.0 in 2025.
  • Per our database at Business Quant, Sanara MedTech's Gains from Sales and Divestitures skyrocketed by 15480.64% in 2022 and then plummeted by 3799.88% in 2023.
  • Quarter analysis of 5 years shows Sanara MedTech's Gains from Sales and Divestitures stood at $54417.0 in 2021, then surged by 183.56% to $154307.0 in 2022, then fell by 10.75% to $137720.0 in 2023, then decreased by 23.12% to $105875.0 in 2024, then rose by 16.73% to $123591.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $123591.0 for Q3 2025, versus $113252.0 for Q2 2025 and $62151.0 for Q1 2025.